Rezolute Inc Stock

$3.95

3.95% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Internet services

Overview Dividends Analysts Charts News Strategies

Rezolute Inc Stock price

$3.95

-0.54 12.03% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.15 3.95%

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Internet services

Key metrics

Market capitalization	$239.11m
Enterprise Value	$154.00m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	2.90
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-77.15m
Cash position	$86.89m
EPS (TTM) EPS	$-1.16
P/E forward	negative
Short interest	4.97%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Rezolute Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Rezolute Inc forecast:

9x Buy

100%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Rezolute Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Rezolute Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.03 0.03	81% 81% -
Gross Profit	-0.03 -0.03	81% 81% -
- Selling and Administrative Expenses	17 17	27% 27% -
- Research and Development Expense	60 60	26% 26% -
EBITDA	-77 -77	26% 26% -
- Depreciation and Amortization	0.03 0.03	81% 81% -
EBIT (Operating Income) EBIT	-77 -77	25% 25% -
Net Profit	-73 -73	25% 25% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Rezolute Inc Stock News

Neutral

GlobeNewsWire

●

7 days ago

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025

Neutral

GlobeNewsWire

●

16 days ago

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today ann...

Neutral

GlobeNewsWire

●

20 days ago

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:

More Rezolute Inc News

Company Profile

Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Nevan Elam
Employees	59
Founded	2010
Website	www.rezolutebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now